

ASX:NRT

NASDAQ:NVGN

Novogen Ltd  
(Company)

ABN 37 063 259 754

---

### Capital Structure

Ordinary Shares on  
issue:

246 M

---

### Board of Directors

**Dr Graham Kelly**  
Chairman &  
Executive Director

**Steve Coffey**  
Non Executive Director

**John O'Connor**  
Non Executive Director

**Prof Peter Gunning**  
Non Executive Director

## ASX RELEASE

23 January 2015

### NOVOGEN CEO TO PRESENT AT BIOTECH AND MONEY INVESTOR CONFERENCE IN LONDON

Novogen (ASX: NRT; NASDAQ: NVGN), an Australian-US drug discovery company focused on the development of novel therapeutics in the fields of oncology, degenerative disease and regenerative medicine, announced today that Graham Kelly, Ph.D., CEO and Executive Chairman, will present at the Biotech and Money London investor conference held during the 3<sup>rd</sup> - 4<sup>th</sup> of February 2015.

#### About Biotech and Money London

Biotech and Money London 2015 is a two-day congress providing the education, strategies and solutions executives need to enable more effective funding, investment, business planning and partnering within businesses.

It's where life science meets money, investors uncover innovation and pharma seek partners.

For more information visit the website: <http://biotechandmoney.com/london>

#### About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene that is common to all cancer cells. Cells die by respiratory distress and mitochondrial disintegration.

The ATM compounds target the micro-filament component of the cancer cell's cytoskeleton and have been designed to combine with anti-microtubular drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.

The Company pipeline comprises three SBP drug candidates (TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate ('Anisina').

Further information is available on our websites [www.novogen.com](http://www.novogen.com)

For more information please contact:

#### Corporate Contact

Dr. Graham Kelly  
Executive Chairman & CEO Novogen Group  
[Graham.Kelly@novogen.com](mailto:Graham.Kelly@novogen.com)  
+61 (0) 2 9472 4100

#### Media Enquiries

Cristyn Humphreys  
Chief Operating Officer Novogen Group  
[Cristyn.Humphreys@novogen.com](mailto:Cristyn.Humphreys@novogen.com)  
+61 (0) 2 9472 4111